PUBLISHER: Grand View Research | PRODUCT CODE: 1511844
PUBLISHER: Grand View Research | PRODUCT CODE: 1511844
The global primary cells market size is anticipated to reach USD 4.00 billion by 2030, growing at a CAGR of 10.39% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is expected to grow due to the increased demand for monoclonal antibodies, rising cancer research, growing preference for primary human cells over cell lines, and increasing government initiatives for cell-based research.
The surge in chronic diseases globally, such as cancer and autoimmune disorders, has led to a growing demand for targeted therapies like monoclonal antibodies. The adoption of these biopharmaceuticals is on the rise as they offer an effective treatment approach by selectively targeting diseased cells while minimizing the impact on healthy ones. The production of monoclonal antibodies often involves the use of primary cells, which are cells taken directly from living organisms or tissues. Primary cells retain the genetic and phenotypic characteristics of the original tissue or organism from which they were derived, making them more authentic models for studying biological processes and producing antibodies.
Moreover, human primary cells play a crucial role in research and development in the field of cell therapy. Cell therapy involves the transplantation of cells to replace or repair damaged tissues and organs, offering promising treatment options for various diseases and conditions. Human primary cells, derived directly from living tissue, provide a more physiologically relevant model than the immortalized cell lines, making them valuable tools in cell therapy research. Donor-to-donor variability, including HLA type and CMV status, in human primary cells is important for personalized medicine approaches in cell therapy as individual differences are likely to impact treatment outcomes. Furthermore, Contract Research Organizations (CROs) specializing in primary cell derivation provide researchers access to a wide range of services related to isolating and preparing primary cells from diverse tissue sources.